{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:43:34Z","timestamp":1791333814656,"version":"4.3.1"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dengue virus infection has become a global health concern, and no dengue\u2010specific treatment is available. Mosnodenvir is a pan\u2010serotypic dengue antiviral in clinical development. In this Phase 1, open\u2010label study (NCT05201937), high\u2010 and low\u2010dose weekly, and twice weekly maintenance doses (MDs) of mosnodenvir were evaluated following a twice daily loading dose (LD) over 2 days. The utility of a convenient capillary blood sampling device (TASSO\u2010M20) was also explored. Healthy adults were sequentially assigned to receive: 450\u00a0mg twice daily LD, 900\u00a0mg once weekly MD; 450\u00a0mg twice daily LD, 450\u00a0mg twice weekly MD; 150\u00a0mg twice daily LD, 300\u00a0mg once weekly MD; or 150\u00a0mg twice daily LD, 150\u00a0mg twice weekly MD. Mosnodenvir exposure rapidly increased with LD and was maintained during the MD phase. In general, mosnodenvir increased in a dose\u2010proportional manner with similar areas under the concentration\u2010time curve between once weekly and twice weekly MD. The mean terminal elimination half\u2010life across treatments was 6.7\u20108.7 days, supporting less frequent dosing. Safety and tolerability were similar across all treatment regimens. TASSO\u2010M20 was preferred over venipuncture by participants. In summary, mosnodenvir administered weekly or biweekly achieved pharmacokinetic exposures that were found to be safe and well tolerated.<\/jats:p>","DOI":"10.1002\/cpdd.1574","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:20:48Z","timestamp":1752567648000},"page":"960-970","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetics, Safety, and Tolerability of Different Maintenance Dose Regimens of Mosnodenvir (JNJ\u20101802) in Healthy Adult Participants"],"prefix":"10.1002","volume":"14","author":[{"given":"Thomas N.","family":"Kakuda","sequence":"first","affiliation":[{"name":"Johnson &amp; Johnson  San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Harasym","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Spring House  PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemie","family":"Buelens","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Kahnt","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Feys","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Goeyvaerts","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Baguet","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine De","family":"Marez","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Spring House  PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Herrera\u2010Taracena","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Horsham PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freya","family":"Rasschaert","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32560-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-025-06235-3"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107940"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taab146"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0476-8"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.07.010"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmmb.2025.100852"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006965"},{"issue":"8","key":"e_1_2_9_10_1","article-title":"Tracing down the updates on dengue virus\u2010molecular biology, antivirals, and vaccine strategies","volume":"11","author":"Malik S","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1115727"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00531-z"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05790-6"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02336"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1011662"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad284"},{"key":"e_1_2_9_17_1","article-title":"Antiviral activity, safety, and pharmacokinetics of mosnodenvir (JNJ\u20101802) as pre\u2010exposure prophylaxis against dengue virus serotype 3 in a controlled human infection model","author":"Durbin AP","journal-title":"N Engl J Med (manuscript submitted)"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105495"},{"key":"e_1_2_9_19_1","first-page":"419","article-title":"Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta\u2010analysis","volume":"7","author":"Srivastava K","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13411"},{"issue":"8","key":"e_1_2_9_21_1","first-page":"34","article-title":"Increased enrollment efficiency with point\u2010of\u2010care pre\u2010screening","volume":"26","author":"Dubois J","year":"2017","journal-title":"Appl Clin Trials"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000864"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3272"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3025"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16182"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116454"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3135"},{"key":"e_1_2_9_28_1","unstructured":"GoeyvaertsN Woot de TrixheX NeyensM et\u00a0al.Viral kinetic modeling of mosnodenvir prophylaxis against DENV\u20103 in a controlled human infection model.Paper presented at: PAGE; June 3\u20136 2025; Thessaloniki Greece."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000001077"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1574","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1574","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:37:44Z","timestamp":1769863064000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/cpdd.1574"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1574","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"2025-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}